Bacterial Skin Diseases

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-08-06
EMA Authorised: Tenkasi (previously Orbactiv) (oritavancin (diphosphate)) — Menarini International Operations Luxembourg S.A.
EMA has authorised Tenkasi (oritavancin diphosphate) for soft tissue infections and bacterial skin diseases, expanding therapeutic options.